December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.079 -0.081 (-3.76%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Editas (EDIT) Q2 2024 Earnings Call Transcript ↗
Editas (EDIT) Q2 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
Editas Medicine beats Q3 2025 earnings estimates, reports strong revenue growth, and advances its lead gene-editing program, EDIT-401. 
Via Chartmill
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Peering Into Editas Medicine's Recent Short Interest ↗
 
Via Benzinga
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗
Editas Medicine (EDIT) stock shows strong technical uptrends and explosive 597% revenue growth, making it a top pick for momentum investors. 
Via Chartmill
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
News headline image
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Why Editas Medicine Stock Was Skyrocketing This Week ↗
The company's CEO made quite the encouraging statement regarding its immediate future. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for... 
Via Chartmill
News headline image
Can This Beaten-Down Stock Bounce Back? ↗
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success. 
Via The Motley Fool
News headline image
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗
Via The Motley Fool
Topics Workforce
News headline image
2 Beaten-Down Stocks to Avoid ↗
Via The Motley Fool
News headline image
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
News headline image
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗
Via The Motley Fool
News headline image
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
News headline image
1 Stock Down 97% That Could Double, According to Wall Street ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Editas Medicine: A Cautionary Tale for Investors ↗
Via The Motley Fool
News headline image
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential ↗
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
News headline image
What's going on in today's session ↗
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Earnings Scheduled For March 5, 2025 ↗
 
Via Benzinga
News headline image
Top movers in Thursday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.